ERBB2 and metastatic neoplasm: Margetuximab, an anti-HER2 monoclonal antibody, was approved for use with chemotherapy in patients with metastatic HER2+ BC following 2 or more HER2-directed therapies, with at least 1 being for metastatic disease.